European Guidelines On CVD Prevention in Clinical Practice 2016

Download as pdf or txt
Download as pdf or txt
You are on page 1of 21

EUROPEAN

GUIDELINES ON CVD
PREVENTION IN
CLINICAL PRACTICE
2016

Guy De Backer
Ghent University, Ghent, Belgium
2

New 2016 European Guidelines on CVD


Prevention in Clinical Practice

G De Backer
Declaration of interests regarding this
presentation: review coordinator
of these guidelines

www.escardio.org/guidelines
3

2016 European Guidelines on cardiovascular disease prevention


in clinical practice
The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on
Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of
10 societies and by invited experts).
Developed with the special contribution of the European Association for Cardiovascular
Prevention & Rehabilitation (EACPR).
ESC Chairperson Co- Chairperson
Massimo F. Piepoli Arno W. Hoes
Task Force Members: StefanAgewall(Norway),ChristianAlbus(Germany),CarlosBrotons(Spain),
AlbericoL.Catapano(Italy),Marie-ThereseCooney(Ireland),UgoCorr(Italy),BernardCosyns(Belgium),
ChristiDeaton(UK),IanGraham(Ireland),MichaelStephenHall(UK),F.D.RichardHobbs(UK),Maja-LisaLchen
(Norway),HerbertLllgen(Germany),PedroMarques-Vidal(Switzerland),JoepPerk(Sweden),EvaPrescott
(Denmark),JosepRedon(Spain),DimitriosJ.Richter(Greece),NaveedSattar(UK),YvoSmulders
(TheNetherlands),MonicaTiberi(Italy),H.BartvanderWorp(TheNetherlands),InekevanDis(TheNetherlands),
W.M.MoniqueVerschuren(TheNetherlands)
Additional Contributor :SimoneBinno(Italy)
ESC Committee for Practice Guidelines (CPG) and National Cardiac Societies document reviewers: listed in the Appendix.
ESC entities having participated in the development of this document:
Associations: EuropeanAssociationforCardiovascularPrevention&Rehabilitation(EACPR),EuropeanAssociationofCardiovascularImaging(EACVI),
EuropeanAssociationofPercutaneousCardiovascularInterventions(EAPCI),HeartFailureAssociation(HFA).
Councils: CouncilonCardiovascularNursingandAlliedProfessions,CouncilforCardiologyPractice,CouncilonCardiovascularPrimaryCare.
Working Groups: CardiovascularPharmacotherapy

www.escardio.org/guidelines EuropeanHeartJournal2016-doi:10.1093/eurheartj/ehw106
4

Guidelines based upon the principles of teaching

Plato, 424-347 b.C.

1. What is CVD prevention


2. Who needs CVD prevention
3. How is CVD prevention applied
4. Where should CVD prevention be offered

www.escardio.org/guidelines
5

Population-approach to prevent CVD

Prevention Paradox : A large number of


people exposed to a small risk may generate
many more cases of CVD than a small
number exposed to a high risk
Population approach is cost saving and
efficient:
A 10% population-wide reduction in blood
cholesterol, blood pressure and smoking
would save approximately three times
more lives than treating 40% of high-risk
individuals with a statin, three half-dose
anti-hypertensives and aspirin.
www.escardio.org/guidelines
6

Recommendation for cost-effective prevention of


cardiovascular disease NEW

www.escardio.org/guidelines
7

Population-approach to prevent CVD NEW

Levels:
Topics:
Governmental restrictions
Diet
and mandate
Physical activity
Media and education
Tobacco use
Labelling and information
Alcohol abuse
Economic incentives
Schools
Workplaces
Community Setting

www.escardio.org/guidelines
8

Recommendations for population-based approaches to


smoking and other tobacco use (1) NEW

www.escardio.org/guidelines
9

SCORE chart:
chart 10-year risk
of fatal CVD based on the
following risk factors: age,
sex, smoking, systolic
blood pressure, total
cholesterol

www.escardio.org/guidelines
10

And what about the other 100+ CV risk factors?

hs-CRP ?
Lp(a) ?
stress ?
body mass index? waist-hip ratio ?
intima-media thickness?
coronary calcium score?

etcetera

www.escardio.org/guidelines
11

Examples of risk modifiers that


(1) have risk reclassification potential and (2) are feasible

www.escardio.org/guidelines
12

Risk categories

Very high-risk Subjectswithanyofthefollowing:


DocumentedCVD,clinicalorunequivocalonimaging.DocumentedclinicalCVD
includespreviousAMI,ACS,coronaryrevascularizationandotherarterial
revascularizationprocedures,strokeandTIA,aorticaneurysmandPAD.
UnequivocallydocumentedCVDonimagingincludessignificantplaqueon
coronaryangiographyorcarotidultrasound.ItdoesNOTincludesomeincreasein
continuousimagingparameterssuchasintimamediathicknessofthecarotid
artery.
DMwithtargetorgandamagesuchasproteinuriaorwithamajorriskfactorsuch
assmokingormarkedhypercholesterolaemiaormarkedhypertension.
SevereCKD(GFR<30mL/min/1.73m 2).
AcalculatedSCORE10%.
High-risk Subjectswith:
Markedlyelevatedsingleriskfactors,inparticularcholesterol>8mmol/L
(>310mg/dL)(e.g.infamilialhypercholesterolaemia)orBP180/110mmHg.
MostotherpeoplewithDM(withtheexceptionofyoungpeoplewithtype1DM
andwithoutmajorriskfactorsthatmaybeatlowormoderaterisk).
ModerateCKD(GFR3059mL/min/1.73m2).
AcalculatedSCORE5%and<10%.
SCOREis1%and<5%at10years.Manymiddleagedsubjectsbelongtothis
Moderate-risk
category.
Low-risk SCORE<1%.

www.escardio.org/guidelines
13

Risk Factor Targets

* Smoking: No exposure to tobacco in any form.


* Diet : Low in saturated fat with a focus on wholegrain
products, vegetables, fruit and fish.
Physical activity: At least 150 minutes a week of
moderate aerobic PA (30 minutes for 5 days/week) or 75
minutes a week of vigorous aerobic PA (15 minutes for 5
days/week) or a combination thereof.
Body weight: BMI 2025 kg/m2.
Waist circumference:
<94 cm (men)or <80 cm (women).
* HbA1c in patients with DM : < 7.0% (< 53 mmol/mol)

www.escardio.org/guidelines
14

Lipids

LDL-C is the primary target:

Very high risk: < 1.8 mmol/L (< 70 mg/dL) OR a reduction of at least 50% if the
baseline LDL-C is between 1.8 and 3.5 mmol/L ( 70 and 135 mg/dL)
High risk : < 2.6 mmol/L (< 100 mg/dL) OR a reduction of at least 50% if the
baseline LDL-C is between 2.6 and 5.2 mmol/L ( 100 and 200 mg/dL).
Low to Moderate risk : < 3.0 mmol/L ( < 115 mg/dL)

www.escardio.org/guidelines
15

Blood pressure targets

SBP should be lowered to < 140 mmHg (and DBP to <


90 mmHg) in all treated hypertensive patients < 60
years old.(I,B)
In patients > 60 years old with SBP 160 mmHg, the
treatment goal is to reduce SBP to between 150 and
140 mmHg.(I,B)
In fit patients <80 years old, a target SBP < 140 mmHg
may be considered if treatment is well tolerated. In
some of these patients a target SBP <120 mmHg may
be considered when they are at (very) high risk and
can tolerate multiple antihypertensive drugs.(IIb,B)

www.escardio.org/guidelines
16

Blood pressure targets

In individuals >80 years and with initial SBP 160


mmHg, it is recommended to reduce SBP to between
150 and 140 mmHg provided they are in good physical
and mental conditions.(I,B)

In frail elderly patients, it should be considered to be


careful in terms of treatment intensity (e.g. number of
antihypertensive drugs) and BP targets, and clinical
effects of treatment should be carefully
monitored.(IIa,B)

www.escardio.org/guidelines
17

Major new key messages since 2012. WHO?

Relevant groups
In womenriskisdeferredbyapproximately10years
In persons > 60 yearsofagetheriskthresholds
shouldbeinterpretedmorelenientlyanduncritical
initiationofdrugtreatmentsshouldbediscouraged.
In younger patients,lowabsoluteriskmayimplicatea
veryhighrelativerisk,anduseoftherelativeriskchart
mayhelp

www.escardio.org/guidelines
18

2016 European Guidelines on CVD Prevention in


Clinical Practice Web addenda

Web Contents
How to intervene at the individual level:
Atrial fibrillation
Coronary artery disease
Chronic heart failure
Cerebrovascular disease
Peripheral artery disease
Web Figures
Web Tables
Web References

www.escardio.org/guidelines
19

2016 European Guidelines on CVD Prevention in


Clinical Practice

To do and not to do messages:


Recommendations for:
- cardiovascular risk assessment
- how to estimate CV risk
- how to intervene
- achieving medication and healthy lifestyle
adherence
- CVD prevention implementation

www.escardio.org/guidelines
EUROPEAN CVD PREVENTION IN CLINICAL PRACTICE
(2016)

The Pocket Guidelines


are available at the
registration area from
Sunday 28 August
afternoon

www.escardio.org/guidelines
21

2016 European Guidelines on CVD Prevention in


Clinical Practice

Thank You for


Your
Attention

www.escardio.org/guidelines

You might also like